New Recruiting Trial: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
WHY IT MATTERS
This is the first trial testing difelikefalin specifically in adolescents on hemodialysis with moderate-to-severe pruritus — a condition that significantly impacts quality of life but has limited treatment options for younger patients.
Researchers are testing a new medicine called difelikefalin to see if it's safe and works well for teenagers on kidney dialysis who have severe itching. Itching is a common problem for dialysis patients that can really affect their quality of life. This study will check whether the medicine helps reduce itching and what side effects it might cause.
NCT ID: NCT06593392 Title: Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus Status: RECRUITING Phase: PHASE2 Sponsor: Vifor Fresenius Medical Care Renal Pharma Start date: 2026-04-09 URL: https://clinicaltrials.gov/study/NCT06593392 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you're a teenager on hemodialysis with moderate-to-severe itching, ask your nephrologist if you meet the eligibility criteria for this trial, as enrollment is currently open.